Navigate
X
    QualityStocks
  • 18 years ago

DOR BioPharma, Inc. (OTC BB: DORB)

DOR BioPharma, Inc. (OTC BB: DORB), a late-stage biopharmaceutical company, is committed to developing products that treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases; in addition to vaccines for certain bioterrorism agents. orBec®, DOR’s lead product, is a potent, locally acting corticosteroid being developed to treat gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of bone marrow transplantation. For further information, visit the Company’s web site at www.dorbiopharma.com.

Tags Rodman & Renshaw
Related Post
  1. Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

    In the United States alone, close to one million people are living with MS, with…

  2. Why Verbal Skills Aren’t Enough: WRAP’s New Doctrine Aims to Give Officers a Lawful Next Step

    California's SB 230 requires agencies to incorporate de-escalation and alternatives to force into their use-of-force…

  3. Beeline Holdings Inc. (NASDAQ: BLNE) Partners with Loft 100 Studios to Examine the Mortgage Market and New Approaches to Homeownership

    The partnership will focus on the production of a 45-minute “Bizumentary” examining current challenges and…